Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)Linda Stein Gold, Kim Papp, Manish R. Patel et al.|British Journal of Dermatology|2023Cited by 22